Destiny Pharma appoints non-executive directors

Saturday 25 June 2022
Destiny Pharma Plc
Appointee name
James Stearns, Aled Williams and Nigel Brooksby

United Kingdom

Destiny Pharma, the UK developer of anti-infective medicines, has appointed three non-executive directors to its board of directors: James Stearns, Aled Williams and Nigel Brooksby. Mr Stearns is the chief investment officer for Europe and the US of China Medical System Holdings Ltd. He has considerable experience in the financial markets having worked on the sellside at Panmure Gordon and the buyside at LivingBridge.

Mr Williams is chief executive of Enthera Pharmaceuticals Srl. He has more than 25 years of leadership experience in the pharma industry as well as experience as a manager of biotech companies. Mr Brooksby has extensive experience in the life science sector including formerly serving as a member of the Sanofi SA executive committee in Europe and North America.

Destiny Pharma announced the appointments on 26 May 2022.

Copyright 2022 Evernow Publishing Ltd